Open19.880 | Close19.830 |
Vol / Avg.356.639K / 329.373K | Mkt Cap728.055M |
Day Range19.600 - 20.120 | 52 Wk Range18.840 - 33.400 |
Bicycle Therapeutics Stock (NASDAQ: BCYC) stock price, news, charts, stock research, profile.
Open19.880 | Close19.830 |
Vol / Avg.356.639K / 329.373K | Mkt Cap728.055M |
Day Range19.600 - 20.120 | 52 Wk Range18.840 - 33.400 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.170 | (EXPECTED) 2023-11-02 | |||||
REV | 13.090M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.290 | -1.410 | -0.1200 | ||||
REV | 4.580M | 11.397M | 6.817M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-12 | B. Riley Securities | Kalpit Patel | Upgrades | NeutralBuy | Announces | - | 33.00 |
2023-09-12 | Cantor Fitzgerald | Li Watsek | Reiterates | OverweightOverweight | Maintains | - | 65.00 |
2023-09-12 | JMP Securities | Reni Benjamin | Reiterates | Market OutperformMarket Outperform | Maintains | - | 44.00 |
2023-09-12 | Needham | Ami Fadia | Reiterates | BuyBuy | Maintains | - | 46.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BCYC | Bicycle Therapeutics | -0.5% | 728.1M |
VALN | Valneva | 17.28% | 922.9M |
COGT | Cogent Biosciences | 0.42% | 819.6M |
AMAM | Ambrx Biopharma | 3.76% | 719.3M |
IMTX | Immatics | -3.71% | 835.3M |
You can purchase shares of Bicycle Therapeutics (NASDAQ: BCYC) through any online brokerage.
Other companies in Bicycle Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Immatics (NASDAQ:IMTX) and Pharming (NASDAQ:PHAR).
The latest price target for Bicycle Therapeutics (NASDAQ: BCYC) was reported by B. Riley Securities on Tuesday, September 12, 2023. The analyst firm set a price target for 33.00 expecting BCYC to rise to within 12 months (a possible 66.41% upside). 27 analyst firms have reported ratings in the last year.
The stock price for Bicycle Therapeutics (NASDAQ: BCYC) is $19.83 last updated October 3, 2023 at 8:00 PM UTC.
There is no dividend information for Bicycle Therapeutics.
Bicycle Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Bicycle Therapeutics.
Bicycle Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Bicycle Therapeutics Stock (NASDAQ: BCYC) stock price, news, charts, stock research, profile.
Open19.880 | Close19.830 |
Vol / Avg.356.639K / 329.373K | Mkt Cap728.055M |
Day Range19.600 - 20.120 | 52 Wk Range18.840 - 33.400 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.170 | (EXPECTED) 2023-11-02 | |||||
REV | 13.090M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.290 | -1.410 | -0.1200 | ||||
REV | 4.580M | 11.397M | 6.817M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-12 | B. Riley Securities | Kalpit Patel | Upgrades | NeutralBuy | Announces | - | 33.00 |
2023-09-12 | Cantor Fitzgerald | Li Watsek | Reiterates | OverweightOverweight | Maintains | - | 65.00 |
2023-09-12 | JMP Securities | Reni Benjamin | Reiterates | Market OutperformMarket Outperform | Maintains | - | 44.00 |
2023-09-12 | Needham | Ami Fadia | Reiterates | BuyBuy | Maintains | - | 46.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BCYC | Bicycle Therapeutics | -0.5% | 728.1M |
VALN | Valneva | 17.28% | 922.9M |
COGT | Cogent Biosciences | 0.42% | 819.6M |
AMAM | Ambrx Biopharma | 3.76% | 719.3M |
IMTX | Immatics | -3.71% | 835.3M |
You can purchase shares of Bicycle Therapeutics (NASDAQ: BCYC) through any online brokerage.
Other companies in Bicycle Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Immatics (NASDAQ:IMTX) and Pharming (NASDAQ:PHAR).
The latest price target for Bicycle Therapeutics (NASDAQ: BCYC) was reported by B. Riley Securities on Tuesday, September 12, 2023. The analyst firm set a price target for 33.00 expecting BCYC to rise to within 12 months (a possible 66.41% upside). 27 analyst firms have reported ratings in the last year.
The stock price for Bicycle Therapeutics (NASDAQ: BCYC) is $19.83 last updated October 3, 2023 at 8:00 PM UTC.
There is no dividend information for Bicycle Therapeutics.
Bicycle Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Bicycle Therapeutics.
Bicycle Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Bicycle Therapeutics Stock (NASDAQ: BCYC) stock price, news, charts, stock research, profile.
Open19.880 | Close19.830 |
Vol / Avg.356.639K / 329.373K | Mkt Cap728.055M |
Day Range19.600 - 20.120 | 52 Wk Range18.840 - 33.400 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.170 | (EXPECTED) 2023-11-02 | |||||
REV | 13.090M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.290 | -1.410 | -0.1200 | ||||
REV | 4.580M | 11.397M | 6.817M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-12 | B. Riley Securities | Kalpit Patel | Upgrades | NeutralBuy | Announces | - | 33.00 |
2023-09-12 | Cantor Fitzgerald | Li Watsek | Reiterates | OverweightOverweight | Maintains | - | 65.00 |
2023-09-12 | JMP Securities | Reni Benjamin | Reiterates | Market OutperformMarket Outperform | Maintains | - | 44.00 |
2023-09-12 | Needham | Ami Fadia | Reiterates | BuyBuy | Maintains | - | 46.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BCYC | Bicycle Therapeutics | -0.5% | 728.1M |
VALN | Valneva | 17.28% | 922.9M |
COGT | Cogent Biosciences | 0.42% | 819.6M |
AMAM | Ambrx Biopharma | 3.76% | 719.3M |
IMTX | Immatics | -3.71% | 835.3M |
You can purchase shares of Bicycle Therapeutics (NASDAQ: BCYC) through any online brokerage.
Other companies in Bicycle Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Immatics (NASDAQ:IMTX) and Pharming (NASDAQ:PHAR).
The latest price target for Bicycle Therapeutics (NASDAQ: BCYC) was reported by B. Riley Securities on Tuesday, September 12, 2023. The analyst firm set a price target for 33.00 expecting BCYC to rise to within 12 months (a possible 66.41% upside). 27 analyst firms have reported ratings in the last year.
The stock price for Bicycle Therapeutics (NASDAQ: BCYC) is $19.83 last updated October 3, 2023 at 8:00 PM UTC.
There is no dividend information for Bicycle Therapeutics.
Bicycle Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Bicycle Therapeutics.
Bicycle Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Bicycle Therapeutics Stock (NASDAQ: BCYC) stock price, news, charts, stock research, profile.
Open19.880 | Close19.830 |
Vol / Avg.356.639K / 329.373K | Mkt Cap728.055M |
Day Range19.600 - 20.120 | 52 Wk Range18.840 - 33.400 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.170 | (EXPECTED) 2023-11-02 | |||||
REV | 13.090M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.290 | -1.410 | -0.1200 | ||||
REV | 4.580M | 11.397M | 6.817M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-12 | B. Riley Securities | Kalpit Patel | Upgrades | NeutralBuy | Announces | - | 33.00 |
2023-09-12 | Cantor Fitzgerald | Li Watsek | Reiterates | OverweightOverweight | Maintains | - | 65.00 |
2023-09-12 | JMP Securities | Reni Benjamin | Reiterates | Market OutperformMarket Outperform | Maintains | - | 44.00 |
2023-09-12 | Needham | Ami Fadia | Reiterates | BuyBuy | Maintains | - | 46.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BCYC | Bicycle Therapeutics | -0.5% | 728.1M |
VALN | Valneva | 17.28% | 922.9M |
COGT | Cogent Biosciences | 0.42% | 819.6M |
AMAM | Ambrx Biopharma | 3.76% | 719.3M |
IMTX | Immatics | -3.71% | 835.3M |
You can purchase shares of Bicycle Therapeutics (NASDAQ: BCYC) through any online brokerage.
Other companies in Bicycle Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Immatics (NASDAQ:IMTX) and Pharming (NASDAQ:PHAR).
The latest price target for Bicycle Therapeutics (NASDAQ: BCYC) was reported by B. Riley Securities on Tuesday, September 12, 2023. The analyst firm set a price target for 33.00 expecting BCYC to rise to within 12 months (a possible 66.41% upside). 27 analyst firms have reported ratings in the last year.
The stock price for Bicycle Therapeutics (NASDAQ: BCYC) is $19.83 last updated October 3, 2023 at 8:00 PM UTC.
There is no dividend information for Bicycle Therapeutics.
Bicycle Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Bicycle Therapeutics.
Bicycle Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Bicycle Therapeutics Stock (NASDAQ: BCYC) stock price, news, charts, stock research, profile.
Open19.880 | Close19.830 |
Vol / Avg.356.639K / 329.373K | Mkt Cap728.055M |
Day Range19.600 - 20.120 | 52 Wk Range18.840 - 33.400 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.170 | (EXPECTED) 2023-11-02 | |||||
REV | 13.090M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.290 | -1.410 | -0.1200 | ||||
REV | 4.580M | 11.397M | 6.817M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-12 | B. Riley Securities | Kalpit Patel | Upgrades | NeutralBuy | Announces | - | 33.00 |
2023-09-12 | Cantor Fitzgerald | Li Watsek | Reiterates | OverweightOverweight | Maintains | - | 65.00 |
2023-09-12 | JMP Securities | Reni Benjamin | Reiterates | Market OutperformMarket Outperform | Maintains | - | 44.00 |
2023-09-12 | Needham | Ami Fadia | Reiterates | BuyBuy | Maintains | - | 46.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BCYC | Bicycle Therapeutics | -0.5% | 728.1M |
VALN | Valneva | 17.28% | 922.9M |
COGT | Cogent Biosciences | 0.42% | 819.6M |
AMAM | Ambrx Biopharma | 3.76% | 719.3M |
IMTX | Immatics | -3.71% | 835.3M |
You can purchase shares of Bicycle Therapeutics (NASDAQ: BCYC) through any online brokerage.
Other companies in Bicycle Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Immatics (NASDAQ:IMTX) and Pharming (NASDAQ:PHAR).
The latest price target for Bicycle Therapeutics (NASDAQ: BCYC) was reported by B. Riley Securities on Tuesday, September 12, 2023. The analyst firm set a price target for 33.00 expecting BCYC to rise to within 12 months (a possible 66.41% upside). 27 analyst firms have reported ratings in the last year.
The stock price for Bicycle Therapeutics (NASDAQ: BCYC) is $19.83 last updated October 3, 2023 at 8:00 PM UTC.
There is no dividend information for Bicycle Therapeutics.
Bicycle Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Bicycle Therapeutics.
Bicycle Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Bicycle Therapeutics Stock (NASDAQ: BCYC) stock price, news, charts, stock research, profile.
Open19.880 | Close19.830 |
Vol / Avg.356.639K / 329.373K | Mkt Cap728.055M |
Day Range19.600 - 20.120 | 52 Wk Range18.840 - 33.400 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.170 | (EXPECTED) 2023-11-02 | |||||
REV | 13.090M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.290 | -1.410 | -0.1200 | ||||
REV | 4.580M | 11.397M | 6.817M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-12 | B. Riley Securities | Kalpit Patel | Upgrades | NeutralBuy | Announces | - | 33.00 |
2023-09-12 | Cantor Fitzgerald | Li Watsek | Reiterates | OverweightOverweight | Maintains | - | 65.00 |
2023-09-12 | JMP Securities | Reni Benjamin | Reiterates | Market OutperformMarket Outperform | Maintains | - | 44.00 |
2023-09-12 | Needham | Ami Fadia | Reiterates | BuyBuy | Maintains | - | 46.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BCYC | Bicycle Therapeutics | -0.5% | 728.1M |
VALN | Valneva | 17.28% | 922.9M |
COGT | Cogent Biosciences | 0.42% | 819.6M |
AMAM | Ambrx Biopharma | 3.76% | 719.3M |
IMTX | Immatics | -3.71% | 835.3M |
You can purchase shares of Bicycle Therapeutics (NASDAQ: BCYC) through any online brokerage.
Other companies in Bicycle Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Immatics (NASDAQ:IMTX) and Pharming (NASDAQ:PHAR).
The latest price target for Bicycle Therapeutics (NASDAQ: BCYC) was reported by B. Riley Securities on Tuesday, September 12, 2023. The analyst firm set a price target for 33.00 expecting BCYC to rise to within 12 months (a possible 66.41% upside). 27 analyst firms have reported ratings in the last year.
The stock price for Bicycle Therapeutics (NASDAQ: BCYC) is $19.83 last updated October 3, 2023 at 8:00 PM UTC.
There is no dividend information for Bicycle Therapeutics.
Bicycle Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Bicycle Therapeutics.
Bicycle Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Bicycle Therapeutics Stock (NASDAQ: BCYC) stock price, news, charts, stock research, profile.
Open19.880 | Close19.830 |
Vol / Avg.356.639K / 329.373K | Mkt Cap728.055M |
Day Range19.600 - 20.120 | 52 Wk Range18.840 - 33.400 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.170 | (EXPECTED) 2023-11-02 | |||||
REV | 13.090M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.290 | -1.410 | -0.1200 | ||||
REV | 4.580M | 11.397M | 6.817M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-12 | B. Riley Securities | Kalpit Patel | Upgrades | NeutralBuy | Announces | - | 33.00 |
2023-09-12 | Cantor Fitzgerald | Li Watsek | Reiterates | OverweightOverweight | Maintains | - | 65.00 |
2023-09-12 | JMP Securities | Reni Benjamin | Reiterates | Market OutperformMarket Outperform | Maintains | - | 44.00 |
2023-09-12 | Needham | Ami Fadia | Reiterates | BuyBuy | Maintains | - | 46.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BCYC | Bicycle Therapeutics | -0.5% | 728.1M |
VALN | Valneva | 17.28% | 922.9M |
COGT | Cogent Biosciences | 0.42% | 819.6M |
AMAM | Ambrx Biopharma | 3.76% | 719.3M |
IMTX | Immatics | -3.71% | 835.3M |
You can purchase shares of Bicycle Therapeutics (NASDAQ: BCYC) through any online brokerage.
Other companies in Bicycle Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Immatics (NASDAQ:IMTX) and Pharming (NASDAQ:PHAR).
The latest price target for Bicycle Therapeutics (NASDAQ: BCYC) was reported by B. Riley Securities on Tuesday, September 12, 2023. The analyst firm set a price target for 33.00 expecting BCYC to rise to within 12 months (a possible 66.41% upside). 27 analyst firms have reported ratings in the last year.
The stock price for Bicycle Therapeutics (NASDAQ: BCYC) is $19.83 last updated October 3, 2023 at 8:00 PM UTC.
There is no dividend information for Bicycle Therapeutics.
Bicycle Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Bicycle Therapeutics.
Bicycle Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Bicycle Therapeutics Stock (NASDAQ: BCYC) stock price, news, charts, stock research, profile.
Open19.880 | Close19.830 |
Vol / Avg.356.639K / 329.373K | Mkt Cap728.055M |
Day Range19.600 - 20.120 | 52 Wk Range18.840 - 33.400 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.170 | (EXPECTED) 2023-11-02 | |||||
REV | 13.090M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.290 | -1.410 | -0.1200 | ||||
REV | 4.580M | 11.397M | 6.817M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-12 | B. Riley Securities | Kalpit Patel | Upgrades | NeutralBuy | Announces | - | 33.00 |
2023-09-12 | Cantor Fitzgerald | Li Watsek | Reiterates | OverweightOverweight | Maintains | - | 65.00 |
2023-09-12 | JMP Securities | Reni Benjamin | Reiterates | Market OutperformMarket Outperform | Maintains | - | 44.00 |
2023-09-12 | Needham | Ami Fadia | Reiterates | BuyBuy | Maintains | - | 46.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BCYC | Bicycle Therapeutics | -0.5% | 728.1M |
VALN | Valneva | 17.28% | 922.9M |
COGT | Cogent Biosciences | 0.42% | 819.6M |
AMAM | Ambrx Biopharma | 3.76% | 719.3M |
IMTX | Immatics | -3.71% | 835.3M |
You can purchase shares of Bicycle Therapeutics (NASDAQ: BCYC) through any online brokerage.
Other companies in Bicycle Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Immatics (NASDAQ:IMTX) and Pharming (NASDAQ:PHAR).
The latest price target for Bicycle Therapeutics (NASDAQ: BCYC) was reported by B. Riley Securities on Tuesday, September 12, 2023. The analyst firm set a price target for 33.00 expecting BCYC to rise to within 12 months (a possible 66.41% upside). 27 analyst firms have reported ratings in the last year.
The stock price for Bicycle Therapeutics (NASDAQ: BCYC) is $19.83 last updated October 3, 2023 at 8:00 PM UTC.
There is no dividend information for Bicycle Therapeutics.
Bicycle Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Bicycle Therapeutics.
Bicycle Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Bicycle Therapeutics Stock (NASDAQ: BCYC) stock price, news, charts, stock research, profile.
Open19.880 | Close19.830 |
Vol / Avg.356.639K / 329.373K | Mkt Cap728.055M |
Day Range19.600 - 20.120 | 52 Wk Range18.840 - 33.400 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.170 | (EXPECTED) 2023-11-02 | |||||
REV | 13.090M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.290 | -1.410 | -0.1200 | ||||
REV | 4.580M | 11.397M | 6.817M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-12 | B. Riley Securities | Kalpit Patel | Upgrades | NeutralBuy | Announces | - | 33.00 |
2023-09-12 | Cantor Fitzgerald | Li Watsek | Reiterates | OverweightOverweight | Maintains | - | 65.00 |
2023-09-12 | JMP Securities | Reni Benjamin | Reiterates | Market OutperformMarket Outperform | Maintains | - | 44.00 |
2023-09-12 | Needham | Ami Fadia | Reiterates | BuyBuy | Maintains | - | 46.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BCYC | Bicycle Therapeutics | -0.5% | 728.1M |
VALN | Valneva | 17.28% | 922.9M |
COGT | Cogent Biosciences | 0.42% | 819.6M |
AMAM | Ambrx Biopharma | 3.76% | 719.3M |
IMTX | Immatics | -3.71% | 835.3M |
You can purchase shares of Bicycle Therapeutics (NASDAQ: BCYC) through any online brokerage.
Other companies in Bicycle Therapeutics’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Ambrx Biopharma (NASDAQ:AMAM), Immatics (NASDAQ:IMTX) and Pharming (NASDAQ:PHAR).
The latest price target for Bicycle Therapeutics (NASDAQ: BCYC) was reported by B. Riley Securities on Tuesday, September 12, 2023. The analyst firm set a price target for 33.00 expecting BCYC to rise to within 12 months (a possible 66.41% upside). 27 analyst firms have reported ratings in the last year.
The stock price for Bicycle Therapeutics (NASDAQ: BCYC) is $19.83 last updated October 3, 2023 at 8:00 PM UTC.
There is no dividend information for Bicycle Therapeutics.
Bicycle Therapeutics’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Bicycle Therapeutics.
Bicycle Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.